If you’ve landed on this page, you’ve probably noticed something on every product listing in our catalog: a line stating that the compound is sold “for laboratory research use only — not for human or veterinary use.” That’s not boilerplate legal filler we tacked on to cover ourselves. It reflects a real, well-documented body of scientific and regulatory concern about what happens when compounds like these are used outside a laboratory setting, without medical supervision, and without pharmaceutical-grade quality control. This article explains why that distinction matters, and what the published literature actually says about the risk categories involved.
Why “Research Use Only” Is Not Just a Label
Every compound in our catalog — GLP-1 receptor agonist analogs, growth hormone secretagogues, experimental repair peptides like BPC-157 and TB-500, melanocortin peptides, and longevity-adjacent molecules like NAD+ precursors and Epitalon — exists somewhere on a spectrum between “has an FDA- or Health Canada-approved pharmaceutical cousin” and “has never been tested in a controlled human trial at all.” Even where an approved analog exists (semaglutide and tirzepatide are the clearest examples), the research-grade version sold as a bulk chemical is not the same regulated, quality-tested product dispensed by a pharmacy. It has not gone through the same manufacturing controls, stability testing, or sterility assurance.
Health Canada has been explicit about this. In a public advisory on unauthorized injectable peptides, the agency stated that labelling a product “for research use only — not for human consumption” does not make it legal for human use or exempt it from regulatory requirements, and it specifically warned Canadians against buying or using peptide products marketed this way for injection. That advisory, along with parallel FDA enforcement actions against peptide sellers, is part of why the research-use framing exists — and why it needs to be taken seriously rather than treated as a technicality.
What the Literature Says: Categories of Risk
Safety unknowns from limited or absent human trials
For a substantial share of the compounds discussed in the peptide research space — BPC-157, TB-500, GHK-Cu in injectable form, KPV, Epitalon, and various NAD+-related peptides — there are no completed, large-scale, randomized, placebo-controlled human trials. Much of the published data comes from animal studies, cell-culture work, or small, uncontrolled human case reports. Regulatory and toxicology reviewers have flagged this repeatedly: without controlled human trials, a complete human safety profile simply does not exist. That means the dosing thresholds, interaction risks, and long-term effects that exist for approved drugs simply have not been established for these substances.
Contamination and purity risks from unregulated sourcing
Because research chemicals bypass pharmaceutical manufacturing standards, quality control is not guaranteed. Health Canada’s advisory noted that seized unauthorized peptide products have been found to contain too much, too little, or none of the labeled active ingredient — and in some cases contained unlisted or hazardous contaminants such as solvents, heavy metals, glass or plastic particulates, bacteria, fungi, or endotoxins. Non-sterile compounding of an injectable product introduces a separate risk of infection at the injection site or systemically. None of these risks are theoretical; they are the specific failure modes regulators have documented in the market.
Contraindications identified in the approved-drug literature
Where an FDA- or Health Canada-approved version of a compound exists, its prescribing label often identifies specific populations or conditions associated with elevated risk. For GLP-1 receptor agonists such as semaglutide and tirzepatide, the approved product labeling contraindicates use in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, based on thyroid C-cell tumor findings in animal studies. The labeling also carries warnings about acute pancreatitis, including rare but serious hemorrhagic or necrotizing cases. For human chorionic gonadotropin (HCG), approved labeling identifies contraindications including precocious puberty and androgen-dependent tumors, and describes risks in pregnancy along with serious reactions such as ovarian hyperstimulation and thromboembolism when used off-label or without monitoring. For growth hormone secretagogues, supraphysiological or unsupervised dosing has been associated with acromegaly-like symptoms (joint pain, fluid retention, carpal tunnel), and impaired glucose control in people with existing insulin resistance or diabetes. None of this literature was generated with unsupervised, self-administered use of unregulated research-grade material in mind — it describes what happens under close clinical monitoring, and the risk profile of unsupervised use is, by definition, less understood, not better.
Dangers of self-dosing without medical supervision
Even when a compound’s mechanism is well characterized, using it correctly requires knowing the true concentration and purity of what’s in the vial, calibrating a dose to an individual’s health status, and monitoring for adverse reactions — all things that require clinical training and oversight. Case literature on melanocortin peptides like Melanotan-2, for example, documents adverse outcomes including eruption of new or changing moles, case reports of melanoma, priapism, rhabdomyolysis, and other serious effects in people who self-administered the compound outside of medical supervision. These are the kinds of outcomes that emerge specifically when a compound with real biological activity is used without the safeguards a clinical setting provides.
Populations Described as Facing Elevated or Poorly Characterized Risk
Across the regulatory and clinical literature reviewed for compounds in these classes, certain groups are repeatedly flagged as facing higher or less well-understood risk:
- Pregnant or nursing individuals — several of these compound classes carry documented or suspected risks to fetal development, and safety in pregnancy and lactation has generally not been established.
- People with a personal or family history of certain endocrine cancers (notably medullary thyroid carcinoma or MEN2 syndrome) — a specific, named contraindication for GLP-1 receptor agonist analogs.
- People with a history of pancreatitis — a recognized warning area for GLP-1 receptor agonist analogs.
- People with pre-existing heart, kidney, or liver conditions — several compound classes carry reports of organ-specific stress or injury with unsupervised use.
- Minors — none of these products are studied, approved, or appropriate for use in children or adolescents.
This is not an exhaustive clinical list, and it should not be read as one. It reflects recurring themes in the safety literature and regulatory communications reviewed, not a substitute for individualized medical guidance.
Our Position
Great Lakes Peptide Co. sells the products in our catalog exclusively for in-vitro and laboratory research use by qualified individuals and institutions. They are not sold, marketed, or intended for human consumption, injection, or any form of personal use, and nothing on this site should be read as an endorsement of using these compounds outside a licensed research setting. If you have a health goal — weight management, recovery from injury, hormonal optimization, or anything else these compound classes are sometimes discussed in connection with — the appropriate and safe path is a conversation with a licensed physician about approved treatment options, monitored dosing, and pharmaceutical-grade products. That conversation, not a research chemical purchased online, is where legitimate health decisions belong.